Public Title Status Last Date Modified
A Randomized, Placebo-Controlled Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of PG04 Ointment in Subjects Colonized with Staphylococcus aureus . . . Completed 06 Oct 2021
A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma . . . Ongoing 26 Nov 2020
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients with COVID-19 Pending 11 Apr 2022
A Study of Guselkumab in Participants with Active Psoriatic Arthritis Ongoing 06 Jun 2022
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) . . . Completed 11 Feb 2022
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and L . . . Ongoing 23 Mar 2022
A Study of SCTA01 in Severe Patients with COVID-19 Terminated 30 Nov -0001
A study of the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension . . . Completed 13 Nov 2019
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA) . . . Completed 13 Apr 2021
A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of . . . Completed 28 Sep 2020
A study to determine the safety and immunogenicity of a new vaccine for Polio in healthy infants Completed 05 Mar 2020
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease . . . Completed 20 Jan 2021
A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus . . . Ongoing 15 Mar 2022
A study to evaluate the performance of a thermistor-based device to measure respiratory rate Ongoing 30 Nov -0001
A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney disease . . . Ongoing 29 Jun 2022
A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository For . . . Ongoing 06 Jul 2020
A three-year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active psoriatic arthritis . . . Completed 25 Jan 2022
A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer . . . Completed 10 Jun 2020
ACTIV-2: Adapt Out COVID Ongoing 30 Nov -0001
An adaptive seamless randomized, double-blind, placebo controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients . . . Terminated 20 May 2021
An Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in High-Risk Outpatients With COVID-19 (MAOP3 Trial) . . . Ongoing 20 Dec 2021
An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Inten . . . Terminated 17 Nov 2021
An exploratory maintenance trial of BI 655064 in patients with lupus nephritis Ongoing 06 May 2021
An Extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension . . . Terminated 09 Jun 2021
An extension study to provide treatment with Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following core study TX05-03. . . . Ongoing 16 Jul 2020
©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date